within Pharmacolibrary.Drugs.ATC.N;

model N05CA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 1.1666666666666668e-06,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05CA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Barbital is a long-acting barbiturate, historically used as a sedative and hypnotic agent for the treatment of insomnia and to induce sleep before surgery. It was one of the first barbiturates introduced to medical practice, but it is now largely obsolete and not approved for current therapeutic use due to safety concerns and the availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for adult humans; no primary literature with full PK models found.</p><h4>References</h4><ol><li><p>Frey, HH, &amp; Löscher, W (1980). Pharmacokinetics of carbamazepine in the dog. <i>Archives internationales de pharmacodynamie et de therapie</i> 243(2) 180–191. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7377892/&quot;>https://pubmed.ncbi.nlm.nih.gov/7377892</a></p></li><li><p>Stephens, HR, et al., &amp; Sandborn, EB (1978). Absorption and distribution of sodium [2-14C]barbital in tissues of normal and dystrophic mice. <i>Canadian journal of physiology and pharmacology</i> 56(1) 76–82. DOI:<a href=&quot;https://doi.org/10.1139/y78-011&quot;>10.1139/y78-011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/638861/&quot;>https://pubmed.ncbi.nlm.nih.gov/638861</a></p></li><li><p>Meshali, MM, &amp; Nightingale, CH (1976). Effect of alpha tocopherol (vitamin E) deficiency on intestinal transport of passively absorbed drugs. <i>Journal of pharmaceutical sciences</i> 65(3) 344–348. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600650307&quot;>10.1002/jps.2600650307</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1263079/&quot;>https://pubmed.ncbi.nlm.nih.gov/1263079</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05CA04;
